FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Bicara Therapeutics in a research note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($1.81) per share for the year, up from their previous forecast of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating and a $13.01 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

A number of other research firms have also recently weighed in on BCAX. HC Wainwright upped their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $13.26 on Wednesday. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The stock’s 50-day moving average is $13.10 and its two-hundred day moving average is $17.73.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company acquired a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $582,000. FMR LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $57,913,000. Walleye Capital LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $809,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $462,000. Finally, Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics during the third quarter worth about $229,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.